NCT00145158 2022-10-10
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
Ludwig Institute for Cancer Research
Phase 1/2 Terminated
Clinical Trials
12 trialsNCT00199836 2022-10-10
A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT00145145 2022-10-07
Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 1/2 Terminated
NCT00490529 2020-01-13
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Stanford University
Phase 2 Completed
NCT00471471 2017-06-22
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
University of Pittsburgh
Phase 1 Completed
NCT00880581 2017-03-14
A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
Stanford University
Phase 2 Completed
NCT00233506 2017-02-06
A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated
University of Iowa
Phase 1 Completed
NCT00226993 2016-12-01
Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.
Stanford University
Phase 1/2 Withdrawn
NCT00438880 2016-02-04
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT00824733 2016-01-14
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00085189 2014-05-22
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
University of Southern California
Phase 2 Completed
NCT00669292 2010-09-09
Phaseâ… /â…¡ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer
Wakayama Medical University
Phase 1/2 Unknown